🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Qingfu Zhang

Sinopec (China)

ORCID: 0000-0002-9891-1296

Also affiliated with Hebei Medical University, Duke University, Third Hospital of Hebei Medical University, Duke Medical Center, Henan Provincial People's Hospital, First Hospital of China Medical University, Taian City Central Hospital, Zhejiang University, China Medical University

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer”.

Protein Arginine Methyltransferase 5 Promotes pICln-Dependent Androgen Receptor Transcription in Castration-Resistant Prostate Cancer

Cancer Research(2020)10.1158/0008-5472.can-20-1228
N/A
0DataRank · unranked
40 citations

Shuyi Fang, Jake L. Owens, Sheng Liu, Xufeng Chen, Qingfu Zhang +11 more

Data from Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46

(2023)10.1158/1078-0432.c.6527663
N/A
0DataRank · unranked
0 citations

Shaoxi Niu, Weiyu Chen, Qingfu Zhang, Yulei Tao, Weihao Chen +10 more

1633P Phase III study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): TALAPRO-2 (TP-2) China cohort

Annals of Oncology(2024)10.1016/j.annonc.2024.08.1714
N/A
0DataRank · unranked
0 citations

D. Ye, Hanxu Guo, Yuchong Yang, Bing Xue, Xiao Zhang +15 more